Results 131 to 140 of about 8,127 (167)

Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases. [PDF]

Oncologist
Scafetta R, Donato M, Gullotta C, Guarino A, Fiore C, Sisca L, Speziale E, Troiano R, Foderaro S, Venuti F, Vilardi FA, Ricozzi V, Iuliani M, Simonetti S, Cavaliere S, Cortellini A, La Cesa A, Botticelli A, Scagnoli S, Pisegna S, Criscitiello C, Chirco A, D'Alessandro S, Pedersini R, Sposetti C, Tiberi E, D'Auria G, Vergati M, Mazzotta M, Caputo R, Verrazzo A, Rossino MG, Domati F, Piombino C, Di Lisa FS, Filomeno L, Arcuri T, Puce F, Riva F, Palleschi M, Sirico M, Piras M, Stucci LS, De Lisi D, Orsaria P, Grasso A, Ippolito E, Ramella S, Visani L, Bertini N, Bonaparte I, Gori S, Rossi L, Meattini I, Tagliaferri B, Caffo O, Bonomo MV, Portarena I, Irelli A, Cretella E, Porta C, Bianchini G, Fabbri MA, De Giorgi U, Vici P, Toss A, Garrone O, De Laurentiis M, Villa F, Berardi R, Minelli M, Altomare V, Vernieri C, Curigliano G, Vincenzi B, Tonini G, Santini D, Pantano F.   +77 more
europepmc   +1 more source

Single-nucleus transcriptomics, pharmacokinetics, and pharmacodynamics of CDK4/6 and mTOR inhibition in a Phase 0/1 trial of recurrent high-grade glioma. [PDF]

Neuro Oncol
Johnson KC, Tien AC, Jiang J, McNamara J, Chang YW, Montgomery C, DeSantis A, Elena-Sanchez L, Fujita Y, Kim S, Spitzer A, Gabriel P, Flynn WF, Courtois ET, Hong A, Harmon J, Umemura Y, Tovmasyan A, Li J, Mehta S, Verhaak RGW, Sanai N.   +21 more
europepmc   +1 more source

"Carry-Over" Effect of CDK4/6 Inhibitors in Adjuvant Therapy for Hormone Receptor (HR)-Positive/HER2-Negative Early Breast Cancer: Clinical Evidence and Molecular Approach. [PDF]

Biomedicines
Valencia G, Morante Z, Ferreyra Y, Jacome R, Rioja P, Saavedra A, Neciosup S, Vidaurre T, Gómez HL.   +8 more
europepmc   +1 more source

Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study. [PDF]

Curr Oncol
Seyyar M, Kalem A, Sali M, Karabuğa B, Sahin TK, Dişli AK, Türkel A, Karadurmuş B, Şahin Hafızoğlu E, Avcı N, Bilgetekin I, Köse Baytemur N, Uguztemur E, Oflazoğlu U, Gür HB, Hacıbekiroğlu İ, Akkuş AF, Topaloğlu S, Bayramgil A, Dülgar Kaya Ö, Yazıcı M, Şakalar T, Akay S, Majidova N, Guliyev M, Alan Ö, Gülcü S, Eren T, İmamoğlu Gİ, Güren AK, Köstek O, Ünlü A, Ozturk B, Aydın E, Safarov S, Doğan B, Tükenmez MA, Demir T, Şahin E, Erdemoğlu E, Keskin Uzundere F, Bütün O, Karabulut B, Uzun M, Baydaş T, Karaman E, Arak H, Ekinci F, Aykan MB, Ertürk İ, Guven DC, Deligönül A, Karaçin C, Ateş Ö, İnanç M, Yeşil H, Aksoy S, Köşeci T, Ökten İN, Yıldırım HÇ, Çabuk D.   +60 more
europepmc   +1 more source

Development and Validation of an SPE-LC-MS Method for the Determination of Epirubicin, Olaparib and Ribociclib in Human Serum. [PDF]

Biomedicines
Popescu MDE, Manda CV, Croitoru O, Calucică DM, Neamțu J, Biță A, Găman AM, Neamțu SD.   +7 more
europepmc   +1 more source

Subsequent Treatments After Progression on Cyclin-Dependent Kinase 4/6 Inhibitors: A Review of the Evidence and a Real-World Data Perspective From Portuguese Hospitals. [PDF]

Cureus
Freitas R, Barroso T, Braga S, Santos CC, Batista M, Chaves A, Cabral S, Fortuna A, Patel V, Araújo J, Duarte T, Cabral TP, Silva S, Viana C, Baptista C, Gonçalves J, Dunões IQ, Eiriz I.   +17 more
europepmc   +1 more source

Supporting adherence to adjuvant CDK4/6 inhibitors in women with early breast cancer (SWEET-PLUS): protocol for a multicentre UK study using qualitative and co-development methods. [PDF]

BMJ Open
Teow P, McGeagh L, Cain H, Todd A, Rehman F, Brett J, Levitt N, Turner M, Stewart SF, Hunt E, Terrado H, Watson E, Sharp L.   +12 more
europepmc   +1 more source

A hypermetabolic pulmonary lesion in a patient with breast cancer. [PDF]

Breathe (Sheff)
Franco G, Promi S, Galbardi I, Paciocco G, Allegranza P, Cangiotti C, Bono F, Zanini U, Pagni F, Faverio P, Guerra L, Cortinovis DL, Cazzaniga ME, Luppi F.   +13 more
europepmc   +1 more source

CDK4/6 inhibitors as conditional immune-priming agents in breast cancer: therapeutic windows, sequencing strategies, and rational combinations with immunotherapy, radiotherapy, and antibody-drug conjugates. [PDF]

Front Immunol
Zheng C, Pan Y, Zheng D, Pan Y.
europepmc   +1 more source

The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective study. [PDF]

Sci Rep
Oruç A, Deliktaş Onur İ, Uyar GC, Şahin TK, Tünbekici S, Arslan Kapuci A, Ulukal Karancı E, Kemik F, Yıldırım Dişli Ş, Ateş Ö, İnanç İmamoğlu G, Aksoy S, Çakar B, Özdemir N, Öztürk B, Selçukbiricik F, Koçak MZ, Karakurt Eryılmaz M, Araz M, Artaç M.   +19 more
europepmc   +1 more source